RYVYL Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RYVYL Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.13M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $18.16M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $65.87M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $32.91M | Mar 26, 2024 |
| FY2022 | Sep 30, 2022 | $10.63M | Aug 10, 2023 |
| FY2022 | Jun 30, 2022 | $6.97M | Aug 10, 2023 |
| FY2022 | Mar 31, 2022 | $4.21M | Aug 10, 2023 |
| FY2022 | Dec 31, 2021 | $26.30M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $8.53M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $10.00M | Mar 30, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Nov 6, 2018 | $90.0K | Feb 7, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.31M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $7.39M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $25.71M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $16.12M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $16.23M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $3.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.09M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $240.3K | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Feb 7, 2020 |
| FY2017 | Dec 31, 2016 | $898.2K | Apr 20, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.53M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($26.83M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($53.10M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($49.24M) | Mar 26, 2024 |
| FY2022 | Sep 30, 2022 | ($15.88M) | Aug 10, 2023 |
| FY2022 | Jun 30, 2022 | $12.09M | Aug 10, 2023 |
| FY2022 | Mar 31, 2022 | ($29.43M) | Aug 10, 2023 |
| FY2022 | Dec 31, 2021 | ($15.32M) | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | ($6.30M) | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | ($306.0K) | Aug 10, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.15M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($27.22M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($12.30M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($37.84M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($29.21M) | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | ($5.10M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($5.61M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.71M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($139.1K) | Feb 7, 2020 |
| FY2017 | Dec 31, 2016 | $113.4K | Apr 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $559.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.85M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.76M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $6.28M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $3.87M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.36M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.26M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $376.9K | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $46.2K | Feb 7, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.04M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $21.19M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $33.16M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($9.34M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($23.01M) | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | ($4.16M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($156.7K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.60M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($110.5K) | Feb 7, 2020 |
| FY2017 | Dec 31, 2016 | $29.9K | Apr 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $47.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $108.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $162.0K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $158.9K | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $6.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $49.8K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $31.3K | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $6.3K | Feb 7, 2020 |
| FY2017 | Dec 31, 2016 | $3.7K | Apr 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.10M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $122.28M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $128.67M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $97.66M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $114.05M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $12.26M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $12.38M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.03M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $92.8K | Feb 7, 2020 |
| FY2017 | Dec 31, 2016 | $123.0K | Apr 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.43M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $123.77M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $105.17M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $99.58M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $84.58M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $11.88M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $17.74M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.95M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $32.0K | Feb 7, 2020 |
| FY2017 | Dec 31, 2016 | $736.9K | Apr 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $668.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.49M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $23.49M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($1.92M) | Mar 28, 2025 |
| FY2022 | Sep 30, 2022 | $15.50M | Aug 10, 2023 |
| FY2022 | Jun 30, 2022 | $22.71M | Aug 10, 2023 |
| FY2022 | Mar 31, 2022 | ($787.0K) | Aug 10, 2023 |
| FY2023 | Dec 31, 2021 | $29.47M | Mar 26, 2024 |
| FY2022 | Sep 30, 2021 | $52.92M | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | $44.59M | Aug 10, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $18.86M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $26.75M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $26.75M | Mar 26, 2024 |
| FY2022 | Mar 31, 2022 | $6.55M | Aug 10, 2023 |
| FY2022 | Dec 31, 2021 | $6.55M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($196.93M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($179.41M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($152.58M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($99.77M) | Mar 26, 2024 |
| FY2022 | Sep 30, 2022 | ($83.76M) | Aug 10, 2023 |
| FY2022 | Jun 30, 2022 | ($67.87M) | Aug 10, 2023 |
| FY2022 | Mar 31, 2022 | ($79.96M) | Aug 10, 2023 |
| FY2022 | Dec 31, 2021 | ($50.54M) | Aug 10, 2023 |
| FY2022 | Sep 30, 2021 | ($35.21M) | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | ($28.91M) | Aug 10, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.43M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.60M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $12.18M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $13.96M | Mar 26, 2024 |
| FY2022 | Sep 30, 2022 | $6.95M | Aug 10, 2023 |
| FY2022 | Jun 30, 2022 | $17.67M | Aug 10, 2023 |
| FY2022 | Mar 31, 2022 | $20.45M | Aug 10, 2023 |
| FY2022 | Dec 31, 2021 | $89.05M | Aug 10, 2023 |
| FY2022 | Sep 30, 2021 | $29.40M | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | $29.74M | Aug 10, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $17.38M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $15.93M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $61.75M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $59.31M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.28M | Mar 31, 2022 |
| FY2016 | Dec 31, 2016 | $7.4K | May 22, 2017 |
| FY2015 | Dec 31, 2015 | $12.3K | Apr 14, 2016 |
| FY2014 | Dec 31, 2014 | $16.8K | Apr 15, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (29) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (140) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (10) | Mar 28, 2025 |
| FY2015 | Dec 31, 2015 | 0 | Apr 14, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Apr 15, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (29) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (140) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (10) | Mar 28, 2025 |
| FY2017 | Dec 31, 2017 | 0 | Apr 20, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 20, 2018 |
| FY2016 | Dec 31, 2015 | 0 | May 22, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Apr 15, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.04M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 229,495 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 6.00M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 4.97M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 42.83M | Aug 10, 2023 |
| FY2021 | Dec 31, 2020 | 30.71M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 28.31M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 166.39M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | 14.45M | Feb 7, 2020 |
| FY2017 | Dec 31, 2016 | 14.45M | Apr 20, 2018 |